Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions

NCT07090525 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Overall Response Rate

Interventions

DRUG: Intracavity injection of bevacizumab 7.5mg/kg plus cisplatin 40mg/m2
DRUG: cisplatin 40mg/m2 intracavity injection

Sponsor

Qingdao Central Hospital